Cangene shares defence costs for Nucleic Acid Sequence Based Amplification (NASBA):
This article was originally published in Clinica
Canadian pharmaceutical company Cangene has agreed to escrow Can$1 million as its share of the defence costs of a threatened legal action by Roche against Akzo. The action has been brought against Akzo's HIV kits which utilise Cangene's NASBA technology (see Clinica No 674, p 13). "This resolution recognises that while Roche filed against Akzo after they had signed the NASBA sale agreement, Cangene has some obligation to assist Akzo in dealing with it," says Cangene's CEO James Rae.